medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2017, Número 3

<< Anterior Siguiente >>

Ann Hepatol 2017; 16 (3)


Drug Induced Liver Injury at a Tertiary Hospital in India: Etiology, Clinical Features and Predictors of Mortality

Rathi C, Pipaliya N, Patel R, Ingle M, Phadke A, Sawant P

Idioma: Ingles.
Referencias bibliográficas: 24
Paginas: 442-450
Archivo PDF: 161.40 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Bjornsson E, Bergmann OM, Bjornsson HK, Kvaran RB, Olafsson S. Incidence, presentation, and outcomes in patients with drug induced liver injury in the general population of Iceland. Gastroenterology 2013; 144: 1419-25.

  2. Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, et al. Features and outcomes of 899 patients with drug-induced liver injury: The DILIN prospective study. Gastroenterology 2015; 148: 1340-52.

  3. Stevens JL, Baker TK. The future of drug safety testing: expanding the view and narrowing the focus. Drug Discov Today 2009; 14: 162-7.

  4. Sgro C, Clinard F, Ouazir K, Chanay H, Allard C, Guilleminet C, Lenoir C, et al. Incidence of drug induced hepatic injuries: a French population-based study. Hepatology 2002; 36: 451-5.

  5. Devarbhavi H, Dierkhising R, Kremers WK, Sandeep MS, Karanth D, Adarsh CK. Single-center experience with drug-induced liver injury from India: causes, outcome, prognosis, and predictors of mortality. Am J Gastroenterol 2010; 105: 2396-404.

  6. de Abajo FJ, Montero D, Madurga M, García Rodríguez LA. Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br J Clin Pharmacol 2004; 58: 71-80.

  7. Chalasani NP, Hayashi PH, Bonkovsky HL, Navarro VJ, Lee WM, Fontana RJ. ACG Clinical Guideline: the Diagnosis and management of idiosyncratic drug induced liver injury. Am J Gastroenterol 2014; 109: 950-6.

  8. Andrade RJ, Lucena MI, Fernandez MC, Pelaez G, Pachkoria K, García-Ruiz E, García-Ruiz B, et al. Drug induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005; 129: 512-21.

  9. Acute Kidney Injury Work Group. Kidney Disease: Improving Global Outcomes (KDIGO) - Clinical Practice Guideline for Acute Kidney Injury. Kidney Inter 2012; 2: 1-138.

  10. Danan G, Benichou C. Causality assessment of adverse reactions to drugs-I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993; 46: 1323-30.

  11. Benichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs-II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol 1993; 46: 1331-6.

  12. Aithal GP, Watkins PB, Andrade RJ, Larrey D, Molokhia M, Takikawa H, Hunt CM, et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther 2011; 89: 806-15.

  13. Treeprasertsuk S, Huntrakul J, Ridtitid W, Kullavanijaya P, Björnsson ES. The predictors of complications in patients with drug-induced liver injury caused by antimicrobial agents. Aliment Pharmacol Ther 2010; 31: 1200-7.

  14. Björnsson E, Olsson R. Outcome and prognostic markers in severe drug induced liver disease. Hepatology 2005; 42: 481-9.

  15. De Valle MB, Av Klinteberg V, Alem N, Olsson R, Björnsson E. Drug-induced liver injury in a Swedish University hospital out-patient hepatology clinic. Aliment Pharmacol Ther 2006; 24: 1187-95.

  16. Lucena MI, Andrade RJ, Kaplowitz N, García-Cortes M, Fernández MC, Romero-Gomez M, Bruguera M, et al. Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex. Hepatology 2009; 49: 2001-9.

  17. Li B, Wang Z, Fang JJ, Xu CY, Chen WX. Evaluation of prognostic markers in severe drug-induced liver disease. World J Gastroenterol 2007; 13: 628-32.

  18. Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med 2006; 354: 731-9.

  19. Assis DN, Navarro VJ. Human drug hepatotoxicity: a contemporary clinical perspective. Expert Opin Drug Metab Toxicol 2009; 5: 463-73.

  20. Robles-Diaz M, Lucena MI, Kaplowitz N, Stephens C, Medina- Cáliz I, González-Jimenez A, Ulzurrun E, et al; Spanish DILI Registry; SLatinDILI Network; Safer and Faster Evidence-based Translation Consortium. Use of Hy's law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury. Gastroenterology 2014; 147: 109-18.

  21. Jeong R, Lee YS, Sohn C, Jeon J, Ahn S, Lim KS. Model for end-stage liver disease score as a predictor of short-term outcome in patients with drug-induced liver injury. Scand J Gastroenterol 2015; 50: 439-46.

  22. García-Cortés M, Stephens C, Lucena MI, Fernández- Castañer A, Andrade RJ; Spanish Group for the Study of Drug-Induced Liver Disease (Grupo de Estudio para las Hepatopatías Asociadas a Medicamentos GEHAM). Causality assessment methods in drug induced liver injury: strengths and weaknesses. J Hepatol 2011; 55: 683-91.

  23. Andrade RJ, Lucena MI, Kaplowitz N, García-Muñoz B, Borraz Y, Pachkoria K, García-Cortés M, et al. Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow- up in a hepatotoxicity registry. Hepatology 2006; 44: 1581-8.

  24. Shapiro MA, Lewis JH. Causality assessment of drug-induced hepatotoxicity: promises and pitfalls. Clin Liver Dis 2007; 11: 477-505.




2020     |     www.medigraphic.com